Innate Pharma/$IPHA
1D1W1MYTD1Y5YMAX
Capital at risk
About Innate Pharma
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
- Ticker
- $IPHA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 164
- Headquarters
- Marseille, France
- Website
- www.innate-pharma.com
Innate Pharma Metrics
BasicAdvanced
$165M
-
-$0.58
0.88
-
Price and volume
Market cap
$165M
Beta
0.88
52-week high
$2.71
52-week low
$1.17
Average daily volume
82K
Financial strength
Current ratio
0.597
Quick ratio
0.597
Long term debt to equity
-0.232
Total debt to equity
-0.499
Interest coverage (TTM)
-124.92%
Profitability
EBITDA (TTM)
-53.662
Gross margin (TTM)
-344.74%
Net profit margin (TTM)
-483.85%
Operating margin (TTM)
-485.25%
Revenue per employee (TTM)
$68,550
Management effectiveness
Return on assets (TTM)
-46.60%
Return on equity (TTM)
268.39%
Valuation
Price to revenue (TTM)
14.943
Price to book
-3.56
Price to tangible book (TTM)
-3.56
Price to free cash flow (TTM)
-3.424
Free cash flow yield (TTM)
-29.21%
Free cash flow per share (TTM)
-0.526
Growth
Revenue change (TTM)
-22.38%
Earnings per share change (TTM)
-6.78%
3-year revenue growth (CAGR)
-42.75%
10-year revenue growth (CAGR)
-13.37%
3-year earnings per share growth (CAGR)
-13.48%
10-year earnings per share growth (CAGR)
28.73%
What the Analysts think about Innate Pharma
Analyst ratings (Buy, Hold, Sell) for Innate Pharma stock.
Analyst projections of the future price of Innate Pharma stock.
Innate Pharma Financial Performance
Revenues and expenses
Innate Pharma Earnings Performance
Company profitability
Upcoming events
No upcoming events
Innate Pharma News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.